Systemic bevacizumab for recurrent respiratory papillomatosis. A case series
AbstractRecurrent respiratory papillomatosis (RRP) is a human papilloma virus (HPV) 6/11 related, predominantly histologically benign neoplasm of the upper and lower airway affecting both younger and older patients. Though potentially declining due to HPV vaccination RRP is still challenging in mana...
Main Authors: | Kristine Grubbe Gregersen, Jeppe Friborg, Claus Andrup Kristensen, Kristian Hveysel Bork |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Acta Oto-Laryngologica Case Reports |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/23772484.2023.2194533 |
Similar Items
-
Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022
by: Laura Torres-Canchala, et al.
Published: (2022-12-01) -
Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients
by: Zengjun Liu, et al.
Published: (2023-04-01) -
A case report describing the use of systemic bevacizumab in the treatment of recurrent respiratory papillomatosis with pulmonary involvement
by: Amy O'Brien, et al.
Published: (2023-12-01) -
Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report
by: Rebecca Maunsell, et al.
Published: (2017-09-01) -
Recurrent respiratory papillomatosis: analysis of the economic impact generated by surgical treatment
by: Juan Antonio Lugo, et al.
Published: (2018-08-01)